This Non-Muscle Invasive Bladder Cancer market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The non-muscle invasive bladder cancer market size has grown strongly in recent years. It will grow from $3.46 billion in 2024 to $3.67 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth during the historical period can be attributed to an aging population, increased healthcare spending, improved healthcare infrastructure, the expansion of telemedicine, and a rise in smoking rates.
The non-muscle invasive bladder cancer market size is expected to see strong growth in the next few years. It will grow to $4.61 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. Projected growth in the forecast period is expected to be driven by the rising adoption of targeted therapies, an increasing focus on personalized medicine, growing investments in oncology research, heightened demand for minimally invasive procedures, and a rising incidence of chronic bladder conditions. Key trends anticipated include advancements in technology, the development of precision medicine, the integration of artificial intelligence, the expansion of telemedicine services, and the adoption of digital health tools.
The demand for minimally invasive procedures is anticipated to drive the growth of the non-muscle invasive bladder cancer market. These procedures involve surgical techniques utilizing small incisions and specialized instruments, resulting in less tissue damage, reduced pain, shorter recovery times, and minimal scarring compared to traditional open surgery. Factors such as shorter recovery periods, improved patient outcomes, and a growing aging population contribute to the rising emphasis on minimally invasive techniques, enhancing patient safety, satisfaction, and healthcare efficiency. Non-muscle invasive bladder cancer facilitates these procedures through localized treatments such as transurethral resection and intravesical therapy, which target tumors without extensive surgical intervention. For example, in August 2023, The Aesthetic Society reported that Americans spent over $11.8 billion on aesthetic procedures, reflecting a 2% increase from the previous year. Consequently, the increasing demand for minimally invasive procedures is boosting the non-muscle invasive bladder cancer market.
The focus on personalized medicine is expected to further fuel the growth of the non-muscle invasive bladder cancer market. Personalized medicine tailors medical treatments to an individual’s genetic profile, lifestyle, and environment to achieve more effective outcomes. This approach is gaining momentum due to advancements in genomic research, improved diagnostic tools, and a rising demand for targeted treatments. Non-muscle invasive bladder cancer aligns with personalized medicine by enabling customized treatment plans based on specific tumor characteristics, genetic markers, and patient profiles. For instance, the Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 novel personalized therapies for rare diseases in 2023, compared to six approvals in 2022. This focus on personalized approaches is significantly contributing to the market’s growth.
Key players in the non-muscle invasive bladder cancer market are advancing immunotherapy to enhance treatment options and patient outcomes. Immunotherapy utilizes the body’s immune system to detect and combat cancer by boosting or activating immune responses. For instance, in March 2024, ImmunityBio Inc., a biotechnology company, received FDA approval for ANKTIVA (N-803) to treat patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) featuring carcinoma in situ (CIS), with or without papillary tumors. This approval, based on promising clinical trial results, highlights ANKTIVA’s effectiveness when combined with Bacillus Calmette-Guérin (BCG), offering a viable option for patients unresponsive to standard BCG therapy. ANKTIVA, an innovative IL-15 agonist immunotherapy, works by stimulating natural killer (NK) cells and CD8+ killer T cells, enhancing the immune system's ability to target and destroy cancer cells.
Major players in the non-muscle invasive bladder cancer market are Johnson & Johnson, Janssen Research & Development LLC, Merck & Co. Inc., AstraZeneca plc, Moderna Inc., Astellas Pharma US Inc., Ferring Pharmaceuticals, EMD Serono Inc., Fidia Farmaceutici SpA, Genentech Inc., Aura Biosciences Inc., UroGen Pharma Ltd., Asieris Pharmaceuticals, Protara Therapeutics Inc., Hamlet Pharma AB, Istari Oncology Inc., Heat Biologics Inc., Telormedix SA, Viventia Bio Inc., Theralase Technologies Inc., Vaxiion Therapeutics Inc., ImmunityBio Inc., Altor BioScience Corporation, SURGE Therapeutics Inc.
North America was the largest region in the non-muscle invasive bladder cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in non-muscle invasive bladder cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the non-muscle invasive bladder cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Non-muscle invasive bladder cancer (NMIBC) is a type of bladder cancer localized to the inner layers of the bladder wall, without infiltration into the muscle layer. It is generally diagnosed at an early stage and can often be effectively managed through treatments such as transurethral resection, intravesical therapy, or close monitoring.
The main stages of NMIBC include carcinoma in situ (CIS), T1 stage, and Ta stage. Carcinoma in situ refers to abnormal cells confined to the bladder lining without spreading to deeper tissues. Treatment options for NMIBC include immunotherapy, chemotherapy, surgery, intravesical therapy, and others, with tumors categorized as low-grade or high-grade. The end users for NMIBC treatments include hospital pharmacies, retail pharmacies, and online pharmacies.
The non-muscle invasive bladder cancer market research report is one of a series of new reports that provides non-muscle invasive bladder cancer market statistics, including non-muscle invasive bladder cancer industry global market size, regional shares, competitors with a non-muscle invasive bladder cancer market share, detailed non-muscle invasive bladder cancer market segments, market trends and opportunities, and any further data you may need to thrive in the non-muscle invasive bladder cancer industry. This non-muscle invasive bladder cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The non-muscle invasive bladder cancer market consists of revenues earned by entities by providing services such as diagnostic services, patient support services, and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-muscle invasive bladder cancer market also includes sales of molecular profiling kits and bladder instillation devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The non-muscle invasive bladder cancer market size has grown strongly in recent years. It will grow from $3.46 billion in 2024 to $3.67 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth during the historical period can be attributed to an aging population, increased healthcare spending, improved healthcare infrastructure, the expansion of telemedicine, and a rise in smoking rates.
The non-muscle invasive bladder cancer market size is expected to see strong growth in the next few years. It will grow to $4.61 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. Projected growth in the forecast period is expected to be driven by the rising adoption of targeted therapies, an increasing focus on personalized medicine, growing investments in oncology research, heightened demand for minimally invasive procedures, and a rising incidence of chronic bladder conditions. Key trends anticipated include advancements in technology, the development of precision medicine, the integration of artificial intelligence, the expansion of telemedicine services, and the adoption of digital health tools.
The demand for minimally invasive procedures is anticipated to drive the growth of the non-muscle invasive bladder cancer market. These procedures involve surgical techniques utilizing small incisions and specialized instruments, resulting in less tissue damage, reduced pain, shorter recovery times, and minimal scarring compared to traditional open surgery. Factors such as shorter recovery periods, improved patient outcomes, and a growing aging population contribute to the rising emphasis on minimally invasive techniques, enhancing patient safety, satisfaction, and healthcare efficiency. Non-muscle invasive bladder cancer facilitates these procedures through localized treatments such as transurethral resection and intravesical therapy, which target tumors without extensive surgical intervention. For example, in August 2023, The Aesthetic Society reported that Americans spent over $11.8 billion on aesthetic procedures, reflecting a 2% increase from the previous year. Consequently, the increasing demand for minimally invasive procedures is boosting the non-muscle invasive bladder cancer market.
The focus on personalized medicine is expected to further fuel the growth of the non-muscle invasive bladder cancer market. Personalized medicine tailors medical treatments to an individual’s genetic profile, lifestyle, and environment to achieve more effective outcomes. This approach is gaining momentum due to advancements in genomic research, improved diagnostic tools, and a rising demand for targeted treatments. Non-muscle invasive bladder cancer aligns with personalized medicine by enabling customized treatment plans based on specific tumor characteristics, genetic markers, and patient profiles. For instance, the Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 novel personalized therapies for rare diseases in 2023, compared to six approvals in 2022. This focus on personalized approaches is significantly contributing to the market’s growth.
Key players in the non-muscle invasive bladder cancer market are advancing immunotherapy to enhance treatment options and patient outcomes. Immunotherapy utilizes the body’s immune system to detect and combat cancer by boosting or activating immune responses. For instance, in March 2024, ImmunityBio Inc., a biotechnology company, received FDA approval for ANKTIVA (N-803) to treat patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) featuring carcinoma in situ (CIS), with or without papillary tumors. This approval, based on promising clinical trial results, highlights ANKTIVA’s effectiveness when combined with Bacillus Calmette-Guérin (BCG), offering a viable option for patients unresponsive to standard BCG therapy. ANKTIVA, an innovative IL-15 agonist immunotherapy, works by stimulating natural killer (NK) cells and CD8+ killer T cells, enhancing the immune system's ability to target and destroy cancer cells.
Major players in the non-muscle invasive bladder cancer market are Johnson & Johnson, Janssen Research & Development LLC, Merck & Co. Inc., AstraZeneca plc, Moderna Inc., Astellas Pharma US Inc., Ferring Pharmaceuticals, EMD Serono Inc., Fidia Farmaceutici SpA, Genentech Inc., Aura Biosciences Inc., UroGen Pharma Ltd., Asieris Pharmaceuticals, Protara Therapeutics Inc., Hamlet Pharma AB, Istari Oncology Inc., Heat Biologics Inc., Telormedix SA, Viventia Bio Inc., Theralase Technologies Inc., Vaxiion Therapeutics Inc., ImmunityBio Inc., Altor BioScience Corporation, SURGE Therapeutics Inc.
North America was the largest region in the non-muscle invasive bladder cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in non-muscle invasive bladder cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the non-muscle invasive bladder cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Non-muscle invasive bladder cancer (NMIBC) is a type of bladder cancer localized to the inner layers of the bladder wall, without infiltration into the muscle layer. It is generally diagnosed at an early stage and can often be effectively managed through treatments such as transurethral resection, intravesical therapy, or close monitoring.
The main stages of NMIBC include carcinoma in situ (CIS), T1 stage, and Ta stage. Carcinoma in situ refers to abnormal cells confined to the bladder lining without spreading to deeper tissues. Treatment options for NMIBC include immunotherapy, chemotherapy, surgery, intravesical therapy, and others, with tumors categorized as low-grade or high-grade. The end users for NMIBC treatments include hospital pharmacies, retail pharmacies, and online pharmacies.
The non-muscle invasive bladder cancer market research report is one of a series of new reports that provides non-muscle invasive bladder cancer market statistics, including non-muscle invasive bladder cancer industry global market size, regional shares, competitors with a non-muscle invasive bladder cancer market share, detailed non-muscle invasive bladder cancer market segments, market trends and opportunities, and any further data you may need to thrive in the non-muscle invasive bladder cancer industry. This non-muscle invasive bladder cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The non-muscle invasive bladder cancer market consists of revenues earned by entities by providing services such as diagnostic services, patient support services, and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-muscle invasive bladder cancer market also includes sales of molecular profiling kits and bladder instillation devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Non-Muscle Invasive Bladder Cancer Market Characteristics3. Non-Muscle Invasive Bladder Cancer Market Trends and Strategies4. Non-Muscle Invasive Bladder Cancer Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Non-Muscle Invasive Bladder Cancer Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Non-Muscle Invasive Bladder Cancer Market34. Recent Developments in the Non-Muscle Invasive Bladder Cancer Market
5. Global Non-Muscle Invasive Bladder Cancer Growth Analysis and Strategic Analysis Framework
6. Non-Muscle Invasive Bladder Cancer Market Segmentation
7. Non-Muscle Invasive Bladder Cancer Market Regional and Country Analysis
8. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market
9. China Non-Muscle Invasive Bladder Cancer Market
10. India Non-Muscle Invasive Bladder Cancer Market
11. Japan Non-Muscle Invasive Bladder Cancer Market
12. Australia Non-Muscle Invasive Bladder Cancer Market
13. Indonesia Non-Muscle Invasive Bladder Cancer Market
14. South Korea Non-Muscle Invasive Bladder Cancer Market
15. Western Europe Non-Muscle Invasive Bladder Cancer Market
16. UK Non-Muscle Invasive Bladder Cancer Market
17. Germany Non-Muscle Invasive Bladder Cancer Market
18. France Non-Muscle Invasive Bladder Cancer Market
19. Italy Non-Muscle Invasive Bladder Cancer Market
20. Spain Non-Muscle Invasive Bladder Cancer Market
21. Eastern Europe Non-Muscle Invasive Bladder Cancer Market
22. Russia Non-Muscle Invasive Bladder Cancer Market
23. North America Non-Muscle Invasive Bladder Cancer Market
24. USA Non-Muscle Invasive Bladder Cancer Market
25. Canada Non-Muscle Invasive Bladder Cancer Market
26. South America Non-Muscle Invasive Bladder Cancer Market
27. Brazil Non-Muscle Invasive Bladder Cancer Market
28. Middle East Non-Muscle Invasive Bladder Cancer Market
29. Africa Non-Muscle Invasive Bladder Cancer Market
30. Non-Muscle Invasive Bladder Cancer Market Competitive Landscape and Company Profiles
31. Non-Muscle Invasive Bladder Cancer Market Other Major and Innovative Companies
35. Non-Muscle Invasive Bladder Cancer Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Non-Muscle Invasive Bladder Cancer Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on non-muscle invasive bladder cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for non-muscle invasive bladder cancer? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-muscle invasive bladder cancer market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Stage: Carcinoma in Situ (CIS); T1 Stage; Ta Stage2) by Treatment: Immunotherapy; Chemotherapy; Surgery; Intravesical Therapy; Others Treatments
3) by Tumor: Low-Grade Tumours; High-Grade Tumours
4) by End-User: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Subsegments:
1) by Carcinoma in Situ (CIS): High-Grade CIS; Low-Grade CIS2) by T1 Stage: T1a Stage (Superficial Tumors); T1b Stage (Invasive Into Lamina Propria)
3) by Ta Stage: Low-Grade Ta Stage; High-Grade Ta Stage
Key Companies Profiled:Johnson & Johnson; Janssen Research & Development LLC; Merck & Co. Inc.; AstraZeneca plc; Moderna Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The companies featured in this Non-Muscle Invasive Bladder Cancer market report include:- Johnson & Johnson
- Janssen Research & Development LLC
- Merck & Co. Inc.
- AstraZeneca plc
- Moderna Inc.
- Astellas Pharma US Inc.
- Ferring Pharmaceuticals
- EMD Serono Inc.
- Fidia Farmaceutici SpA
- Genentech Inc.
- Aura Biosciences Inc.
- UroGen Pharma Ltd.
- Asieris Pharmaceuticals
- Protara Therapeutics Inc.
- Hamlet Pharma AB
- Istari Oncology Inc.
- Heat Biologics Inc.
- Telormedix SA
- Viventia Bio Inc.
- Theralase Technologies Inc.
- Vaxiion Therapeutics Inc.
- ImmunityBio Inc.
- Altor BioScience Corporation
- SURGE Therapeutics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 3.67 Billion |
| Forecasted Market Value ( USD | $ 4.61 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
